Publications
Publishing the Frontiers of Immuno-Oncology
Spotlight Publication
Botensilimab (Fc-enhanced anti-CTLA-4), Balstilimab (PD-1 inhibitor)
Emerging survival plateaus with botensilimab and balstilimab: Pan tumor data from a large phase 1b trial of advanced solid tumors
Oct 17, 2025
,
Gordon et al.
ESMO
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Identification and characterization of an allogeneic iNKT-CAR targeting BCMA.
SITC
Society for Immunotherapy of Cancer (SITC)
June 2, 2022
,
Michelet, et al.
No items found.
INCAGN1876 (GITR Agonist)
A Novel Agonist Antibody (INCAGN01876) That Targets the Costimulatory Receptor GITR.
AACR
American Association for Cancer Research (AACR)
June 2, 2022
,
Gonzalez, et al.
No items found.
AGENT-797 (Allogeneic iNKT Cell Therapy)
Persistence and tissue distribution of Agent-797 – a native allogeneic iNKT cell-therapy drug product.
SITC
Society for Immunotherapy of Cancer (SITC)
June 2, 2022
,
Purbhoo, et al.
No items found.
INCAGN2390 (TIM-3 Antagonist)
INCAGN02390, a Novel Antagonist Antibody That Targets the Co-Inhibitory Receptor TIM-3.
AACR
American Association for Cancer Research (AACR)
June 2, 2022
,
Waight, et al.
No items found.